Enveric Biosciences, Inc. — Earnings
Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | — | — | — |
| 2025-09-30 | $274 | ↑+226.3% | $-2M | ↑+10.1% | -683920.8% |
| 2025-06-30 | $-132 | ↓-277.1% | $-3M | ↓-34.0% | 1908370.5% |
| 2025-03-31 | $2 | ↓-99.7% | $-2M | ↑+11.1% | -109376650.0% |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | $-217 | ↓-109.7% | $-2M | ↑+26.2% | 959996.3% |
| 2024-06-30 | $-35 | ↓-103.8% | $-2M | ↑+70.4% | 5422660.0% |
| 2024-03-31 | $696 | ↑+6427.3% | $-2M | ↑+47.5% | -355936.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q3)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGo deeper
ENVB Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyENVB Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics